Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: Results of the B-CLOSER-I study

Diagnostic Molecular Pathology

Volumn 21, Issue 2, 2012, Pages 69-76

  Vegué, Laia Bernet ^a   Rojo, Federico ^c   Hardisson, David ^d   Iturriagagoitia, Alicia Córdoba ^e   Panadés, Ma José ^f   Velasco, Ana ^f   Bonet, Eugeni López ^g   Muñoz, Rafael Cano ^b   Polo, Luis ^h  

^a HOSPITAL LLUÍS ALCANYÍS   (Spain)

^b HOSPITAL DE LA RIBERA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e Instituto de Investigación Sanitaria de Navarra   (Spain)

^f HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^g HOSPITAL JOSEP TRUETA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

cancer staging; histopathology; lymph nodes; metastasis; molecular detection

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; AXILLARY LYMPH NODE METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER SIZE; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MICROMETASTASIS; MOLECULAR PATHOLOGY; NUCLEIC ACID AMPLIFICATION; ONE STEP NUCLEIC ACID AMPLIFICATION; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; SENTINEL LYMPH NODE METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; KERATIN-19; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84861228688     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e318241117b     Document Type: Article

References (32)

1. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52:1551-1557. (Pubitemid 13018271)
2. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
3. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23: 7703-7720. (Pubitemid 46291835)
4. Tan LK, Giri D, Hummer AJ, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 nodenegative patients with 20-year follow-up. J Clin Oncol. 2008;26: 1803-1809.
5. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364: 412-421.
6. de Boer M, van Dijck JA, Bult P, et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 2010;102:410-425.
7. Jakub JW, Bryant K, Huebner M, et al. The number of axillary lymph nodes involved with metastatic breast cancer does not affect outcome as long as all disease is confined to the sentinel lymph nodes. Ann Surg Oncol. 2011;18:86-93.
8. Cserni G, Amendoeira I, Apostolikas N, et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer. 2003;39:1654-1667. (Pubitemid 36897601)
9. NHS Breast Screening Programme. Pathology Reporting of Breast Disease. NHSBP Publication No. 58. 2005. Available at: http://www.cancerscreening.nhs.uk/ breastscreen/publications/nhsbsp58.html.Accessed August 23, 2011.
10. Schem C, Maass N, Bauerschlag DO, et al. One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Arch. 2009;454:203-210.
11. Snook KL, Layer GT, Jackson PA, et al. Multicentre evaluation of intraoperative molecular analysis of sentinel lymph nodes in breast carcinoma. Br J Surg. 2011;98:527-535.
12. Tamaki Y, Akiyama F, Iwase T, et al. Molecular detection of lymph node metastases in breast cancer patients: results of a multicentertrial using the one-step nucleic acid amplification assay. Clin Cancer Res. 2009;15:2879-2884.
13. Tsujimoto M, Nakabayashi K, Yoshidome K, et al. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13:4807-4816. (Pubitemid 47294788)
14. Bernet L, Cano R, Martínez M, et al. Diagnosis of the sentinel lymph node in breast cancer: a reproducible molecular method. AMulticentric Spanish Study. Histopathology. 2011;58:863-869.
15. Bernet Vegué L, Martínez Benaclocha M, Cano Muñoz R, et al. Molecular diagnosis of sentinel lymph nodes for breast cancer: one step ahead for standardisation. Diagn Mol Pathol. 2011;20:18-21.
16. Verbanac KM, Min CJ, Mannie AE, et al. Long-term follow-up study of a prospective multicenter sentinel node trial: molecular detection of breast cancer sentinel node metastases. Ann Surg Oncol. 2010;17(suppl 3):368-377.
17. Bernet L, Piñero A, Vidal-Sicart S, et al. Actualizacio n del consenso sobre la biopsia selectiva del ganglio centinela en el ca ncer de mama. Revista de Senología y Patología Mamaria. 2010;23:201-208.
18. Devilee P, Tavassoli FA. World Health Organization: Tumours of the Breast and Female Genital Organs. Oxford: Oxford University Press; 2003.
19. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
20. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesteronereceptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
21. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
22. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212-7220.
23. Dupont WD, Plummer WD Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998;19:589-601. (Pubitemid 29057724)
24. Dowlatshahi K, Fan M, Anderson JM, et al. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol. 2001;8:675-681. (Pubitemid 32847934)
25. Weaver DL, Krag DN, Ashikaga T, et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: amulticenter study. Cancer. 2000;88:1099-1107. (Pubitemid 30127672)
26. Hansen NM, Grube B, Ye X, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009;27:4679-4684.
27. de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361:653-663.
28. Meretoja TJ, Vironen JH, Heikkila PS, et al. Outcome of selected breast cancer patients with micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node dissection. J Surg Oncol. 2010;102:215-219.
29. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-432; discussion 432-423.
30. Yegiyants S, Romero LM, Haigh PI, et al. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node. Arch Surg. 2010;145:564-569.
31. Kim HJ, Son BH, Lim WS, et al. Impact of omission of axillary lymph node dissection after negative sentinel lymph node biopsy: 70-month follow-up. Ann Surg Oncol. 2010;17:2126-2131.
32. Parikh RR, Yang Q, Higgins SA, et al. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys. 2008;70:35-42. (Pubitemid 350251027)